Every Form 4 that Rezolute, Inc. (RZLT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RZLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RZLT filings page.
Rezolute, Inc. (RZLT) reported that Chief Commercial Officer Sunil Ratilal Karnawat had 2,267 Common Shares disposed of on September 2, 2026 at $4.50 per share to cover tax withholding obligations arising from the vesting and settlement of Restricted Stock Units. This issuer-mandated "sell to cover" transaction is described as non-discretionary for the reporting person. Following the transaction, he held 69,275 Common Shares directly, plus 8,000 shares in an Individual Retirement Account and 1,898 shares in a Health Savings Account.
Rezolute, Inc. Chief Medical Officer Brian Kenneth Roberts reported a mandatory tax-withholding share disposition tied to vested Restricted Stock Units. On this Form 4, 3,062 common shares were disposed of at $4.99 per share to cover tax withholding obligations under a required “sell to cover” arrangement, which the company elected and which the footnote states was not a discretionary transaction by Roberts. After this event, he held 293,851 common shares directly and 15,500 common shares indirectly through an IRA, indicating that the filing reflects routine equity compensation and related tax handling rather than an open-market sale based on personal trading decisions.
Rezolute, Inc. CEO Nevan C. Elam reported a routine tax-related share disposition. On the transaction date, 8,004 common shares were automatically sold at $4.99 per share to cover tax withholding obligations arising from the vesting and settlement of Restricted Stock Units.
The company elected a mandatory “sell to cover” method for these taxes, so this was not a discretionary market trade by the CEO. After this transaction, Elam directly holds 605,497 common shares of Rezolute.
Rezolute, Inc. CFO Daron Evans reported a tax-related share disposition tied to RSU vesting. On the transaction date, 3,062 common shares at $4.99 per share were disposed of to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The footnote explains this was a mandated “sell to cover” under the company’s election and not a discretionary trade by Evans. Following this transaction, he held 411,400 common shares directly. He also reports indirect holdings, including shares held by his spouse, minor children, and PoC Capital, LLC, a California limited liability company he manages, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Rezolute, Inc. CFO Daron Evans bought 10,000 common shares in an open-market purchase at $2.85 per share. Following this March 30, 2026 transaction, he directly owns 414,462 common shares. The filing also reports additional indirect holdings held by his spouse, minor children, and PoC Capital, LLC, a California LLC he manages, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Rezolute, Inc.’s Chief Medical Officer Brian Kenneth Roberts reported a mandatory share disposition tied to equity compensation. On the RSU vesting date, he disposed of 11,439 common shares to cover tax withholding obligations at a weighted average price of $2.99 per share, with individual sale prices ranging from $2.98 to $3.07. After this tax-withholding transaction, he directly holds 296,913 common shares and indirectly holds 15,500 common shares in an IRA.
Rezolute, Inc. CFO Daron Evans reported a mandated tax-withholding share disposition related to restricted stock units. On this Form 4, he disposed of 11,438 common shares at a weighted average price of $2.99 per share to cover tax obligations from RSU vesting, as required by the company’s sell-to-cover election and not as a discretionary trade. Following the transaction, he directly holds 404,462 common shares. He also reports additional indirect holdings in Rezolute shares held by his spouse, minor children, and PoC Capital LLC, a California limited liability company he manages, with beneficial ownership in the LLC disclaimed except to the extent of his pecuniary interest.
Rezolute, Inc. CEO and director Nevan C. Elam reported a tax-related share disposition. On March 2, 2026, 27,618 common shares were disposed of at a weighted average price of $2.99 per share to cover tax withholding obligations from vested RSUs.
The company required this "sell to cover" transaction, so it was not a discretionary sale by Elam. After the transaction, Elam directly held 613,501 Rezolute common shares.
Rezolute, Inc. director Wladimir Hogenhuis reported an open-market purchase of company stock. On 12/16/2025, he bought 5,650 Rezolute common shares at a price of $1.69 per share, coded as a purchase transaction. Following this trade, he beneficially owns 119,675 common shares in a direct ownership position.
Rezolute, Inc.'s Chief Medical Officer reported buying additional company stock. On 12/16/2025, the officer purchased 28,000 common shares of Rezolute at a price of $1.7 per share. After this transaction, the officer beneficially owned 308,352 common shares directly and 15,500 common shares indirectly through an IRA. This filing highlights increased personal exposure of a senior executive to Rezolute’s equity.
Rezolute, Inc. Chief Financial Officer Daron Evans reported open-market purchases of company stock. On December 15, 2025, he bought 40,000 common shares at a weighted average price of $1.766, in transactions within a range of $1.65 to $1.81. He also reported purchases of 2,500 shares each for two minor children at weighted average prices of $1.785 and $1.79.
Following these transactions, Evans directly owns 415,900 common shares. He also reports indirect beneficial ownership of shares held for three minor children, his spouse, and 40,000 shares held by PoC Capital LLC, a California limited liability company he manages, while disclaiming beneficial ownership of those LLC-held shares beyond his pecuniary interest.
Rezolute, Inc. CEO and director Nevan C. Elam reported purchasing 32,000 common shares of Rezolute on 12/15/2025 at $1.59 per share. Following this transaction, his direct beneficial ownership increased to 641,119 Rezolute common shares.
Rezolute, Inc. insider Sunil Patilal Karnawat, the company’s Chief Commercial Officer, reported open-market purchases of common stock. On 12/15/2025, he bought 12,000 common shares at $1.6199 per share and an additional 100 common shares at $1.6 per share. Following these transactions, he directly owns 71,542 Rezolute common shares, with another 8,000 shares held in an individual retirement account and 1,898 shares held in a health savings account.
Rezolute, Inc. (RZLT) reported an equity award to its Chief Medical Officer, Brian Kenneth Roberts, in a Form 4 filing. On 11/19/2025, he received 123,000 restricted stock units (RSUs) of Rezolute common shares at a price of $0. These RSUs vest annually over three years, with the first portion vesting on December 1, 2026.
On the same date, he was also granted an employee stock option covering 72,000 common shares at an exercise price of $10.16 per share. These options vest at a rate of 1/36th monthly beginning on December 19, 2025 and expire on 11/19/2035. After these transactions, Roberts beneficially owned 280,352 common shares directly, plus 15,500 shares held indirectly in an IRA, and 72,000 stock options.
Rezolute, Inc. (RZLT) reported an equity award to its Chief Commercial Officer. On November 19, 2025, the officer received 32,000 common shares in the form of restricted stock units, granted at a price of $0. After this transaction, the officer held 59,442 common shares directly, plus 8,000 shares in an individual retirement account and 1,898 shares in a health savings account.
The filing also shows a new employee stock option grant for 19,000 options with an exercise price of $10.16 per share, expiring on November 19, 2035. The restricted stock units vest annually over three years starting on December 1, 2026, while the options vest in equal monthly installments over 36 months beginning on December 19, 2025.
Rezolute, Inc. reported new equity awards to its CEO and director, Nevan C. Elam. On 11/19/2025, he received 317,000 common shares as restricted stock units at a price of $0, increasing his beneficial ownership to 609,119 common shares held directly.
He also received an employee stock option to buy 186,000 common shares at an exercise price of $10.16 per share. These options are exercisable through 11/19/2035. The restricted stock units vest annually over three years starting on December 1, 2026, and the options vest in equal monthly installments of 1/36 beginning on December 19, 2025.
Rezolute, Inc. executive equity grants disclosed
Rezolute, Inc. reported that its Chief Financial Officer, Daron Evans, acquired 107,000 restricted stock units of Rezolute common shares on 11/19/2025 at a stated price of $0. These restricted stock units vest annually over a three-year period, with the first portion vesting on December 1, 2026.
Following this transaction, Evans beneficially owns 375,900 Rezolute common shares directly, with additional indirect holdings through family members and PoC Capital, LLC. He also received an employee stock option grant covering 63,000 Rezolute common shares at an exercise price of $10.16 per share, vesting 1/36th monthly beginning on December 19, 2025 and expiring on November 19, 2035.
Rezolute, Inc. director reports new equity awards. On 11/19/2025, a director of Rezolute, Inc. (RZLT) received 21,000 restricted stock units at a stated price of $0, increasing the director’s beneficial ownership to 58,576 common shares. The RSUs fully vest on December 1, 2026, meaning the director will receive the underlying shares only after that date if the vesting conditions are met.
The director also received a stock option grant to buy 12,000 common shares at an exercise price of $10.16 per share. These options are exercisable until November 19, 2035 and fully vest on December 1, 2026. Both awards are reported as directly owned and reflect standard equity-based compensation for board service.
Rezolute, Inc. reported an equity award to a director. A board member received 21,000 common shares in the form of restricted stock units on November 19, 2025, recorded at a price of $0, increasing their directly held stake to 114,025 common shares after the transaction. These restricted stock units fully vest on December 1, 2026.
The director was also granted a stock option covering 12,000 common shares at an exercise price of $10.16 per share, expiring on November 19, 2035. The option grant also fully vests on December 1, 2026, aligning both equity awards to the same vesting date.
Rezolute, Inc. (RZLT) reported a new equity compensation grant to one of its directors. On 11/19/2025, the reporting person acquired 21,000 common shares as a grant of restricted stock units at a price of $0, reflecting stock-based compensation rather than a purchase. After this transaction, the director beneficially owned 21,000 common shares directly.
On the same date, the director also received a stock option to buy 12,000 common shares at an exercise price of $10.16 per share, with the option expiring on 11/19/2035. Both the 21,000 restricted stock units and the 12,000 options are scheduled to fully vest on December 1, 2026, tying the director’s compensation to Rezolute’s future share performance.
Rezolute, Inc. (RZLT) disclosed that director Young‑Jin Kim received new equity awards on 11/19/2025. He was granted 21,000 restricted stock units at a price of $0, which fully vest on December 1, 2026. Following this grant, he directly beneficially owns 170,950 common shares. In addition, he indirectly beneficially owns 8,423,386 common shares held by Handok, Inc., for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Kim was also granted a director stock option to purchase 12,000 common shares at an exercise price of $10.16 per share, with the options fully vesting on December 1, 2026 and expiring on November 19, 2035. These awards increase his potential long‑term equity stake and further align his interests with Rezolute shareholders.
Rezolute, Inc. (RZLT) reported an equity grant to a director. On 11/19/2025, the director received 21,000 restricted stock units of Rezolute common shares at a price of $0, increasing their directly owned common shares to 55,500 after the transaction. The filing also reports a grant of a director stock option for 12,000 common shares at an exercise price of $10.16 per share, expiring on 11/19/2035.
The 21,000 restricted stock units fully vest on December 1, 2026, meaning the director will receive the underlying shares at that time if conditions are met. The 12,000 options become fully exercisable on December 1, 2026, giving the director the right to buy Rezolute shares at $10.16 per share through the expiration date.
Rezolute, Inc. (RZLT) reported an insider equity grant for director Gil M. Labrucherie. On 11/19/2025, he received 21,000 restricted stock units at a price of $0, which fully vest on December 1, 2026. Following this grant, he beneficially owns 55,500 common shares directly and 53,572 common shares indirectly through The Labrucherie Trust dated 9/1/2009.
He was also granted a director stock option for 12,000 common shares at an exercise price of $10.16 per share on 11/19/2025. These options are exercisable until 11/19/2035 and fully vest on December 1, 2026.